Oyster Point Pharma (OYST) Stock Analysis

What Oyster Point Pharma does

Viatris Inc. completed its acquisition of Oyster Point Pharma, Inc. on January 3, 2023. Prior to this, Oyster Point Pharma operated as a commercial-stage biopharmaceutical firm, primarily focused on discovering, developing, and commercializing pharmaceutical treatments for various eye conditions within the United States. The company's principal investigational therapy is TYRVAYA, a nicotinic acetylcholine receptor agonist designed to alleviate the signs and symptoms of dry eye disease. TYRVAYA is also being evaluated in a Phase II clinical trial for its potential application in treating neurotrophic keratopathy. Oyster Point Pharma was founded in 2015 and was headquartered in Princeton, New Jersey.

Key metrics

ETFs linked to OYST

Broad-market and Healthcare sector ETFs an investor holding Oyster Point Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how OYST fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Oyster Point Pharma?

Oyster Point Pharma trades under the ticker OYST on NASDAQ.

Which exchange is OYST listed on?

OYST is listed on NASDAQ.

What sector does Oyster Point Pharma operate in?

Oyster Point Pharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze OYST in a portfolio?

PortView shows OYST's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.